Pharmacology There is a synthetic derivative of lysergic acid amide that has been described as a nootropic

[red22]

N,N-diacetoxyethyl 9,10-dihydrolysergic acid amide

CAS 109002-91-7

AWD 52-39, an ergot derivative with potential nootropic activity. Hoffman, W., Rostock, A., Siegemund, C., & Bartsch, R. 1989. Activitas nervosa superior, 31(1), 56–57

This paper isn't on the Internet, unfortunately.

 

[daturetard]

Though interesting, this isn't really all that surprising to anybody who's taken a lysergamide. Even lsa seeds on their own have the potential to make you think much more deeply, and with being stimulants, it checks out they would work as smart drugs. Especially if you could isolate all the different lysergic acids and have experience with the lone chemicals to compare and see what is doing the most work on your perception of information.

 

[red22]

⌜                  ⌝

AWD 52-39​

AWD 52-39, or AWD-5239, also known as N,N-diacetoxyethyl-9,10-dihydrolysergamide, is a drug described as a "nootropic" (cognitive enhancer) of the lysergamide family related to lysergic acid diethylamide (LSD) that was never marketed.[1][2][3][4][5] It was under development by Arzneimittelwerk Dresden, but development was discontinued.[4] The effects of AWD 52-39 in preclinical studies have been reported.[5][6][7][8] It has been described as a serotonin 5-HT₂ receptor antagonist.[1][2] The drug has been found to enhance learning and memory and to produce antidepressant-like effects in rodents.[3] It appears to act upon vascular serotonin receptors.[7] The chemical synthesis and stereochemistry of AWD 52-39 have been described.[9] The drug was first described in the scientific literature by 1989.[5] It reached phase 2 clinical trials for the treatment of cognition disorders prior to the discontinuation of its development.[1][2]

References​

1. "AWD 5239". AdisInsight. 31 July 1995. Retrieved 4 June 2026.

2. "Delving into the Latest Updates on AWD-5239 with Synapse". Synapse. 16 May 2026. Retrieved 4 June 2026.

3. Hoffmann W, Rostock A, Siegemund C, Bartsch R (1990). "Effects of the novel compound AWD 52-39 on behavioral test methods for evaluation of memory-enhancing drugs". European Journal of Pharmacology. 183 (4): 1480. doi:10.1016/0014-2999(90)94625-8. Retrieved 15 October 2025.

4. Froestl W, Pfeifer A, Muhs A (2013). "Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs". Journal of Alzheimer's Disease. 34 (1): 1–114. doi:10.3233/JAD-121729. PMID 23186990.

5. Hoffman W, Rostock A, Siegemund C, Bartsch R (April 1989). "AWD 52-39, an ergot derivative with potential nootropic activity". Activitas Nervosa Superior. 31 (1): 56–57. PMID 2782003.

6. Brust P, Jordan K (August 1992). "Effects of the nootropic AWD 52-39 on the blood-brain transfer of leucine, choline and glucose in rats after 14-d exposure to ethanol". Die Pharmazie. 47 (8): 616–620. PMID 1438514.

7. Müller H, Glusa E (February 1992). "Effect of AWD 52-39 on vasoconstriction induced by noradrenaline and 5-hydroxytryptamine in vitro and in vivo in rats". Die Pharmazie. 47 (2): 137–139. PMID 1635923.

8. Brust P (1991). "Blood-brain barrier transport under different physiological and pathophysiological circumstances including ischemia". Experimental Pathology. 42 (4): 213–219. doi:10.1016/s0232-1513(11)80068-x. PMID 1959581.

9. Dopke W, Heidenbluth K, Hempel R, Zeigan D, Mugge C (1995). "Synthese und Stereochemie von AWD 52-39" [Synthesis and Stereochemistry of AWD-52-39.]. Pharmazie (in German). 50 (5): 351–354.
⌞                  ⌟
en.wikipedia.org/wiki/AWD_52-39